You are correct delta32. is the mutation. When
Post# of 154134
(Total Views: 396)
Posted On: 05/18/2019 7:40:41 AM
Re: Nt2innvovate #3103
You are correct delta32. is the mutation.
When T-cells are produced by the bone marrow cells and modified in the thymus by type (CD4+ and CD8+) they are naive (not set to attack any particular virus). The primary immune system adapts the T-cells to attack whatever virus the primary is already attacking.
Some of those transformed T-cells further change into memory cells which maintain the adaptations to that particular virus so that if it reappears it can swiftly proliferate and kill off the virus. Which is the whole point behind immunizations.
Since memory T-cells are not produced in marrow and leronlimab does not genetically alter marrow cells it will not shut down production of CCR5 expressive cells.
A full cycle of memory T-cell deaths is 17 years. With the way leronlimab blocks HIV entry it might not take the full 17 years to eliminate HIV. But no bone marrow transplant would be needed.
I hinted at the possibility a month ago. we may have not seen the full potential of Leronlimab yet
When T-cells are produced by the bone marrow cells and modified in the thymus by type (CD4+ and CD8+) they are naive (not set to attack any particular virus). The primary immune system adapts the T-cells to attack whatever virus the primary is already attacking.
Some of those transformed T-cells further change into memory cells which maintain the adaptations to that particular virus so that if it reappears it can swiftly proliferate and kill off the virus. Which is the whole point behind immunizations.
Since memory T-cells are not produced in marrow and leronlimab does not genetically alter marrow cells it will not shut down production of CCR5 expressive cells.
A full cycle of memory T-cell deaths is 17 years. With the way leronlimab blocks HIV entry it might not take the full 17 years to eliminate HIV. But no bone marrow transplant would be needed.
I hinted at the possibility a month ago. we may have not seen the full potential of Leronlimab yet
(0)
(0)